APX 005M

Drug Profile

APX 005M

Alternative Names: APX 005; APX 005M; EPI-0050

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epitomics
  • Developer Apexigen; Parker Institute for Cancer Immunotherapy; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD40 antigen stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer
  • Phase I/II Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 06 Oct 2017 Phase-II clinical trials in Oesophageal cancer and Gastric cancer (Neoadjuvant therapy) in USA (IV) (NCT03165994)
  • 25 Jul 2017 Apexigen and Neon Therapeutics enter into a clinical trial collaboration for a phase Ib trial in Malignant melanoma
  • 25 Jul 2017 Apexigen and Neon Therapeutics plan a phase Ib trial in Malignant melanoma (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top